How should protein S deficiency be managed perioperatively, including anticoagulation and bridging strategies?

Perioperative Management of Protein S Deficiency

Patients with protein S deficiency undergoing surgery should receive therapeutic anticoagulation perioperatively, with careful attention to timing of interruption and resumption based on bleeding risk, avoiding routine bridging therapy unless at very high thrombotic risk.

Risk Stratification and Baseline Approach

Protein S deficiency creates a hypercoagulable state that significantly increases perioperative thrombotic risk 1. The key is balancing thrombosis prevention against bleeding complications:

• High-risk procedures (cardiac surgery, major orthopedic surgery, neurosurgery): These patients require modified anticoagulation protocols
• Standard-risk procedures: Follow general perioperative anticoagulation principles but with heightened vigilance

Preoperative Anticoagulation Management

If on Vitamin K Antagonist (VKA/Warfarin):

• Stop warfarin 5 days before surgery to allow INR normalization 2
• Do NOT routinely bridge with heparin products - the 2024 AHA/ACC guidelines and 2022 ACCP guidelines strongly discourage routine bridging due to increased bleeding without reduction in thromboembolism 2, 3
• Exception: Consider bridging ONLY if patient has additional very high thrombotic risk factors (e.g., recent VTE within 3 months, mechanical mitral valve) 3

If on Direct Oral Anticoagulants (DOACs):

• Avoid DOACs as first-line therapy in protein S deficiency - insufficient data support their use in major thrombophilias; VKAs and low-molecular-weight heparins remain preferred 4
• If already on DOAC, interrupt based on bleeding risk and renal function:
  • High bleeding risk procedures: Stop 2-3 days before (4-5 half-lives) 3
  • Standard bleeding risk: Stop 1-2 days before (2-3 half-lives) 3

Intraoperative Considerations

For Cardiac Surgery Patients:

The cardiac surgery literature provides the most specific guidance for protein S deficiency 1:

• Use modified heparinization protocols: Full heparinization for cardiopulmonary bypass
• Incomplete protamine reversal: Use only partial protamine antagonism (rather than complete reversal) to maintain some anticoagulant effect
• Target INR 2.0 perioperatively when using warfarin-based protocols 1

For Orthopedic Surgery:

• Highest bleeding risk with bridging: Total hip arthroplasty patients bridged with unfractionated heparin had 50% reoperation rate for bleeding complications 5
• Avoid bridging in joint replacement unless absolutely necessary 5

Postoperative Anticoagulation Resumption

Timing Based on Hemostasis:

For VKA (Warfarin):

• Resume 12-24 hours postoperatively once adequate hemostasis achieved 2
• Restart at previous therapeutic dose 2
• Monitor INR closely as perioperative factors (antibiotics, nutrition changes, altered drug clearance) affect levels 2

For DOACs (if used despite recommendations):

• Resume 48-72 hours after high bleeding risk procedures 2
• Can resume as early as 6 hours after low bleeding risk procedures if hemostasis secure 2
• Peak effect occurs in 2-3 hours, so ensure true hemostasis before administration 3

Bridging Postoperatively (Rarely Indicated):

• Assess surgical site hemostasis carefully before any bridging: evaluate drain output amount, character (serous vs bloody), and trend 3
• If bridging deemed necessary: Use therapeutic-dose LMWH (enoxaparin 1 mg/kg BID) 3
• Do not bridge if high bleeding risk (intracranial, spinal, cardiac surgery) - use prophylactic-dose LMWH instead 3

VTE Prophylaxis Considerations

• Once therapeutic anticoagulation resumed, additional VTE prophylaxis typically unnecessary 3
• Exception: High VTE risk surgeries (abdominopelvic cancer, hip/knee replacement) may warrant prophylactic LMWH for 2-3 days until VKA therapeutic or DOAC resumed 3

Critical Pitfalls to Avoid

1. Do not routinely bridge - this is the most important change from older practice patterns. Bridging increases bleeding 2-3 fold without reducing thrombosis 2, 5

2. Incomplete protamine reversal in cardiac surgery - complete reversal may precipitate thrombosis in protein S deficient patients 1

3. Premature postoperative anticoagulation - assess hemostasis objectively before resuming full anticoagulation to avoid devastating bleeding complications 3

4. Using DOACs without adequate evidence - stick with VKAs or LMWH for protein S deficiency until better data emerge 4

5. Ignoring renal function - protein S deficiency doesn't change the need to adjust anticoagulant dosing for renal impairment 2

Multidisciplinary Communication

Ensure clear documentation and communication among surgery, anesthesia, hematology, and pharmacy teams regarding the specific anticoagulation plan, including exact timing of interruption and resumption 3. This coordination is essential given the multiple care transitions and the narrow therapeutic window in these high-risk patients.